How PlexusDx Supports a More Personalized Approach PlexusDx's Precision Peptide Genetic Test examines variants in GLP1R, GIPR, and related metabolic pathwayspredispositions that may help provide context for how your body responds to consistent GLP-1 exposure over time
Furthermore, they also found that 'a balanced dual agonist in mice engineered to lack GLP-1 receptors still induced weight loss, proving that the compounds were not causing weight loss purely by targeting GLP-1' (Molteni, Chen)
Side effects are rare, but some individuals may experience mild pain at the injection site, allergic reactions, or dizziness
Orforglipron (Foundayo) New for 2026 The newest addition to the metabolic toolkit, this is a non-peptide oral medication recently approved by the FDA
The KEAP1NRF2 system and neurodegenerative diseases
Such trials include investigating other GLP-1RAs use in adolescents, the use of GLP-1RAs in young children, and trials involving various possible adverse effects of using these medications in pediatric patients
